To include your compound in the COVID-19 Resource Center, submit it here.

Checkpoint begins Phase I of anti-PD-L1 mAb in cancer

In October, Checkpoint Therapeutics Inc. (NASDAQ:CKPT) began a Phase I trial of CK-301 to treat about 80 checkpoint therapy-naïve

Read the full 194 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE